Filter Results:
(1,253)
Show Results For
- All HBS Web
(1,253)
- People (5)
- News (177)
- Research (922)
- Events (6)
- Multimedia (12)
- Faculty Publications (754)
Show Results For
- All HBS Web
(1,253)
- People (5)
- News (177)
- Research (922)
- Events (6)
- Multimedia (12)
- Faculty Publications (754)
- June 2003 (Revised March 2008)
- Case
Schering-Plough and Genome Therapeutics: Discovering an Asthma Gene
By: Regina E. Herzlinger and Marc Aquino
Personalized medicine requires the identification of mutated genes. Schering-Plough's search for the one related to asthma requires finding families with the disease. Examines the industry that helps conduct such research, including contract research organizations. View Details
Keywords: Health Disorders; Research and Development; Genetics; Pharmaceutical Industry; Pharmaceutical Industry
Herzlinger, Regina E., and Marc Aquino. "Schering-Plough and Genome Therapeutics: Discovering an Asthma Gene." Harvard Business School Case 303-044, June 2003. (Revised March 2008.)
- February 1997 (Revised June 1999)
- Teaching Note
Massachusetts General Hospital: CABG Surgery (A) TN
Teaching Note for (9-696-015). View Details
- November 1995 (Revised March 2004)
- Case
Massachusetts General Hospital: CABG Surgery (A)
By: Steven C. Wheelwright and James Weber
A cross-functional team at Massachusetts General Hospital tries to reengineer the service delivery process (the "care path") for heart bypass surgery (CABG) in order to shorten hospital stays (and lower costs) while maintaining/enhancing the quality of care provided. View Details
Keywords: Health Care and Treatment; Medical Specialties; Business Processes; Mission and Purpose; Product Positioning; Product Marketing; Management Practices and Processes; Customer Satisfaction; Service Delivery; Service Operations; Fair Value Accounting; Ethics; Pharmaceutical Industry; Pharmaceutical Industry; Massachusetts
Wheelwright, Steven C., and James Weber. "Massachusetts General Hospital: CABG Surgery (A)." Harvard Business School Case 696-015, November 1995. (Revised March 2004.)
- September 1997 (Revised October 1997)
- Case
Bayer AG (A)
By: John A. Quelch
Bayer's senior executives convene in Germany to consider submitting a $1 billion bid that would recover the Bayer brand name and trademark cross in North America, both of which were confiscated by the U.S. government after World War I. The group also sets out to assess... View Details
Keywords: Management Teams; Brands and Branding; War; Communication; Trademarks; Acquisition; Government and Politics; Pharmaceutical Industry; Pharmaceutical Industry; Germany; North America; United States
Quelch, John A., and Robin Root. "Bayer AG (A)." Harvard Business School Case 598-031, September 1997. (Revised October 1997.)
- November 1991 (Revised December 1991)
- Case
SmithKline Beecham Animal Health
By: Ray A. Goldberg
Goldberg, Ray A. "SmithKline Beecham Animal Health." Harvard Business School Case 592-053, November 1991. (Revised December 1991.)
- 02 Jul 2001
- Research & Ideas
Ray A. Goldberg
is the blurring of agriculture and pharmaceuticals limited to seeds and plants. Animals are being turned into drug-manufacturing facilities" as well. Thus, Goldberg says, bioengineering may some day lead to animals whose milk, for... View Details
- 12 May 2009
- First Look
First Look: May 12, 2009
Case 809-026 An executive from pharmaceutical company GSK must choose how much to integrate a recently acquired biotechnology firm, Sirtris. Moncef Slaoui, GSK's global head of R&D, championed the acquisition of Sirtris to gain access... View Details
Keywords: Martha Lagace
- 14 Dec 2010
- First Look
First Look: Dec. 14
addresses a decision to replace salesmen netbook PCs with iPhones, including converting the company's sales and customer applications to the iPhone platform. Purchase this case:http://cb.hbsp.harvard.edu/cb/product/911413-PDF-ENG Hikma View Details
Keywords: Sean Silverthorne
- 01 Oct 2008
- Research & Ideas
How Much Time Should CEOs Devote to Customers?
business and the company's strategy. In a service business like Tesco's, the health of the brand depends heavily on the quality of the millions of daily transactions between shoppers and staff. Motivating the front-line personnel is critical. But in the View Details
Keywords: by John Quelch
- 29 Sep 2022
- News
Securing a Resilient Future for Senegal
pharmaceutical sovereignty as key priorities,” Diagne explains. Senegal also wants to boost tourism now that many countries have reopened their borders. The tertiary sector, which took a strong hit through the pandemic, still accounts for... View Details
Keywords: Maureen Harmon
- 22 Feb 2016
- Research & Ideas
The ‘Mother of Fair Trade’ was an Unabashed Price Protectionist
state pharmaceutical licensing exam, opened a drugstore with her husband in Stockton in 1915. Following his death, she became the sole proprietor and later opened two additional drugstores in town. Gleason emerged as a stalwart defender... View Details
- 04 May 2010
- First Look
First Look: May 4
910-409 On July 5, 2004, Pfizer's China team received disappointing news. China's patent review board just invalidated the company's existing patent on one of its most successful drugs, Viagra. Making matters worse, a Guangdong-based View Details
Keywords: Martha Lagace
- 21 Apr 2014
- Research & Ideas
Bio-Piracy: When Western Firms Usurp Eastern Medicine
communities that traditionally use the herb. The paper cites two key examples of local communities benefiting from a firm's herbal patent. In one case, members of Indian Kani tribe received royalties for the pharmaceutical version of the... View Details
- 10 Jun 2008
- First Look
First Look: June 10, 2008
Formula’ Harvard Business School Case 808-127 Robert Wessman took over Actavis in 1999 when it was a failing 90-person domestic generic pharmaceutical maker in Iceland. Within 7 years he had brought Actavis to number 5 worldwide, with... View Details
Keywords: Martha Lagace
- 05 Jul 2004
- Research & Ideas
Radical Change, Entrepreneurial Opportunity
tightly coupled relationships with customers to engage in trials of different product concepts, producers and users can jointly learn about and make sense of the new technology. For instance, Surface Logix, a firm with highly sophisticated, flexible technology called... View Details
- 13 Oct 2016
- News
Adding Muscle to the Fight Against Disease
Stanford, in addition to his Harvard MBA, Blum’s credentials make him well suited to a career in biotech. Prior to joining Cytokinetics, he had experience in sales, marketing, and business development in large and small pharmaceutical... View Details
Keywords: Deborah Blagg
- 10 Jun 2021
- Blog Post
Managing Sustainable Advantage with Key ESG Cofounders, Anne-Marie Schoonbeek and Heleen van Poecke
internship and then later back to McKinsey after graduation, where she focused on both large-cap and startups in the pharmaceuticals and biotech space. “For me, this was a way of making an impact,” said Schoonbeek. van Poecke began her... View Details
- July 2017 (Revised July 2019)
- Supplement
"Doctor My Eyes"--The Acquisition of Bausch & Lomb by Warburg Pincus (B)
By: Nori Gerardo Lietz and Ricardo Andrade
The B Case of "Dr. My Eyes" provides the answer as to what happened after the ending fact pattern in Case A and the imminent choices faced by the protagonist in the primary case. At the end of the Case A, Bess Weatherman of Warburg Pincus, must chose one option of two... View Details
Keywords: Private Equity; Health Care and Treatment; Mergers and Acquisitions; Corporate Governance; Decision Choices and Conditions; Outcome or Result; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry
Lietz, Nori Gerardo, and Ricardo Andrade. "Doctor My Eyes"--The Acquisition of Bausch & Lomb by Warburg Pincus (B). Harvard Business School Supplement 218-029, July 2017. (Revised July 2019.)
- July 2016 (Revised July 2019)
- Teaching Plan
Doctor My Eyes: The Acquisition of Bausch & Lomb by Warburg Pincus (A)
By: Nori Gerardo Lietz and Ricardo Andrade
In early 2010, senior partners at Warburg Pincus met to review a report on Bausch & Lomb Incorporated, the firm's largest investment at the time. Warburg Pincus had led a group of investors in acquiring Bauch & Lomb on October 26, 2007, taking the company private and... View Details
- April 2016 (Revised July 2019)
- Case
"Doctor My Eyes"--The Acquisition of Bausch & Lomb by Warburg Pincus (A)
In early 2010, senior partners at Warburg Pincus met to review a report on Bausch & Lomb Incorporated, the firm's largest investment at the time. Warburg Pincus had led a group of investors in acquiring Bauch & Lomb on October 26, 2007, taking the company private and... View Details
Keywords: Health Care; Mergers ＆ Acquisitions; Governance; Buyout; Private Equity; Finance; Mergers and Acquisitions; Corporate Governance; Health Care and Treatment; Reports; Business Model; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States
Lietz, Nori Gerardo. "Doctor My Eyes"--The Acquisition of Bausch & Lomb by Warburg Pincus (A). Harvard Business School Case 216-021, April 2016. (Revised July 2019.)